open access

Vol 72, No 11-12 (2004)
ORIGINAL PAPERS
Published online: 2008-02-18
Submitted: 2013-02-22
Get Citation

Serum sICAM-1 in patients suffering from allergic rhinitis treated with fexofenadine or fluticasone

Małgorzata Górska-Ciebiada, Maciej Ciebiada, Anna Zakrzewska, Paweł Górski, Iwona Grzelewska-Rzymowska
Pneumonol Alergol Pol 2004;72(11-12):487-492.

open access

Vol 72, No 11-12 (2004)
ORIGINAL PAPERS
Published online: 2008-02-18
Submitted: 2013-02-22

Abstract

The aim of the study was to examine the level of sICAM-1in serum of patients suffering from allergic rhinitis treated with fexofenadine or fluticasone. The study was performed after two weeks duration of the pollen season. Thirty -eight patients sensitized to grass pollen were participated in this study: 15 patients were treated for 10 days with oral fexofenadine (dose: 120 mg/d), 13 patients were treated with intranasal fluticasone (dose:200mcg/d), 10 patients were given oral placebo. Blood sample were collected both in the first and the last day of the treatment. The efficacy was evaluated with the use of symptom score. sICAM-1l level in serum was measured with ELISA method. The results: Mean sICAM-1 level in serum was: in group treated with fexofenadine- 224,5 ng/ml before treatment, 228 ng/ml &#8211; after treatment; in group treated with fluticasone-212ng/ml before treatment, 214ng/ml&#8211; after treatment; in placebo group- 226 ng/ml before treatment, 229 ng/ml&#8211; after treatment. There was no difference in statistical analysis between sICAM-1 values. (p>0,05). In 7 patients treated with fexofenadine serum levels of sICAM-1 significantly decreased from 212ng/ml to 185ng/ml(p<0,05),the same decrease was observed in 7 patients treated with fluticasone: from 233ng/ml to 209ng/ml(p<0,01),and in 6 patients from placebo group: from 219 ng/ml to 205 ng/ml (p<0,01). However in the rest of patient&#8217;s level of sICAM-1 significantly in creased after treatment. Patients treated with fexofenadine showed significant improvements of clinical symptoms (meansymptom score before treatment: 11,3, after treatment-5,3) and symptoms evaluated during laryngological examination (mean symptom score before treatment: 9,5, after treatment- 5,5). Significant improvement of clinical symptoms was also observed in patients treated with fluticasone (mean symptoms core before treatment: 10,7,after treatment 3,6)and symptoms evaluated during laryngological examination (mean symptom score before treatment: 9,2, after treatment- 5,0). No changes were noticed in placebo group (mean clinical symptom score before treatment: 9,0, after treatment 10,3 and mean laryngological symptom score before treatment: 7,5, after treatment 7,7).
Pneumonol. Alergol. Pol. 2004, 72, 487:492

Abstract

The aim of the study was to examine the level of sICAM-1in serum of patients suffering from allergic rhinitis treated with fexofenadine or fluticasone. The study was performed after two weeks duration of the pollen season. Thirty -eight patients sensitized to grass pollen were participated in this study: 15 patients were treated for 10 days with oral fexofenadine (dose: 120 mg/d), 13 patients were treated with intranasal fluticasone (dose:200mcg/d), 10 patients were given oral placebo. Blood sample were collected both in the first and the last day of the treatment. The efficacy was evaluated with the use of symptom score. sICAM-1l level in serum was measured with ELISA method. The results: Mean sICAM-1 level in serum was: in group treated with fexofenadine- 224,5 ng/ml before treatment, 228 ng/ml &#8211; after treatment; in group treated with fluticasone-212ng/ml before treatment, 214ng/ml&#8211; after treatment; in placebo group- 226 ng/ml before treatment, 229 ng/ml&#8211; after treatment. There was no difference in statistical analysis between sICAM-1 values. (p>0,05). In 7 patients treated with fexofenadine serum levels of sICAM-1 significantly decreased from 212ng/ml to 185ng/ml(p<0,05),the same decrease was observed in 7 patients treated with fluticasone: from 233ng/ml to 209ng/ml(p<0,01),and in 6 patients from placebo group: from 219 ng/ml to 205 ng/ml (p<0,01). However in the rest of patient&#8217;s level of sICAM-1 significantly in creased after treatment. Patients treated with fexofenadine showed significant improvements of clinical symptoms (meansymptom score before treatment: 11,3, after treatment-5,3) and symptoms evaluated during laryngological examination (mean symptom score before treatment: 9,5, after treatment- 5,5). Significant improvement of clinical symptoms was also observed in patients treated with fluticasone (mean symptoms core before treatment: 10,7,after treatment 3,6)and symptoms evaluated during laryngological examination (mean symptom score before treatment: 9,2, after treatment- 5,0). No changes were noticed in placebo group (mean clinical symptom score before treatment: 9,0, after treatment 10,3 and mean laryngological symptom score before treatment: 7,5, after treatment 7,7).
Pneumonol. Alergol. Pol. 2004, 72, 487:492
Get Citation

Keywords

seasonal allergic rhinitis; sICAM-1; fexofenadine; fluticasone.

About this article
Title

Serum sICAM-1 in patients suffering from allergic rhinitis treated with fexofenadine or fluticasone

Journal

Advances in Respiratory Medicine

Issue

Vol 72, No 11-12 (2004)

Pages

487-492

Published online

2008-02-18

Bibliographic record

Pneumonol Alergol Pol 2004;72(11-12):487-492.

Keywords

seasonal allergic rhinitis
sICAM-1
fexofenadine
fluticasone.

Authors

Małgorzata Górska-Ciebiada
Maciej Ciebiada
Anna Zakrzewska
Paweł Górski
Iwona Grzelewska-Rzymowska

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl